Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Stopped early
Conditions studied: Progressive Multifocal Leukoencephalopathy
In brief
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).
Key facts
- Study ID
- NCT01211639
- Run by
- Biogen
- People needed
- 24
- Starts
- 2010-10-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2015-01-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- North Central Neurology Associates — Cullman, Alabama, United States
- Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver — Aurora, Colorado, United States
- Rush Medical Center - Rush Multiple Sclerosis Center — Chicago, Illinois, United States
- St. Vincent Hospital, St. Vincent Neuroscience Institute — Indianapolis, Indiana, United States
- Central Neurology — Hastings, Nebraska, United States
- Clinical Research Center UH, The Nebraska Medical Center — Omaha, Nebraska, United States
- NYU Hospital for Joint Disease, MS Care Center — New York, New York, United States
- University of Rochester — Rochester, New York, United States
- Research Site — Cincinnati, Ohio, United States
- Neurology of Bend, LLC — Bend, Oregon, United States
- Research Site — Würzburg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.